Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry

Chest

Volumn 146, Issue 5, 2014, Pages 1263-1273

  Burger, Charles D ^a   Long, Pamela K ^a   Shah, Monarch R ^b   McGoon, Michael D ^c   Miller, Dave P ^b   Romero, Alain J ^d   Benton, Wade W ^d   Safford, Robert E ^a  

^a MAYO CLINIC   (United States)

^b ICON CLINICAL RESEARCH   (United States)

^c MAYO CLINIC   (United States)

^d Actelion Pharmaceuticals US Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLEEDING; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DEVICE REMOVAL; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARENTERAL DRUG ADMINISTRATION; PNEUMONIA; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL RATE; ADOLESCENT; CLINICAL TRIAL; DISEASE MANAGEMENT; FOLLOW UP; HYPERTENSION, PULMONARY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGISTER; STATISTICS AND NUMERICAL DATA; TIME; TRENDS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL RATE; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84909995960     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0193     Document Type: Article

References (21)

1. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012; 31(25):2973-2984.
2. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157.
3. Galiè N, Humbert M, Vachiéry JL, et al; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39(9):1496-1502.
4. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-2100.
5. Jing ZC, Yu ZX, Shen JY, et al; Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183(12):1723-1729.
6. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-1263.
7. Pulido T, Adzerikho I, Channick RN, et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9):809-818.
8. Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013;144(5):1521-1529.
9. Talavera ML, Favaloro LF, Diez MD, Peradejordis MP, Huerta CH, Favaloro RF. Prognostic value of heart failure hospitalization in pulmonary hypertension [abstract]. Eur J Heart Fail. 2011;10(S1):S158.
10. Campo A, Mathai SC, Le Pavec J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J. 2011;38(2):359-367.
11. Haddad F, Peterson T, Fuh E, et al. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail. 2011;4(6):692-699.
12. Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J. 2010;35(6):1286-1293.
13. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61(12):1259-1267.
14. Domsic RT, Chung L, Gordon JK, Cloonan Y, Steen VD. PHAROS Investigators. Survival, hospitalization or need for combination therapy at one year in patients with scleroderma-associated pulmonary arterial hypertension [abstract]. Arthritis Rheum. 2012;64(S10):S310-S311.
15. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923-931.
16. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):5S-12S.
17. Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC. The cost to managed care of managing pulmonary hypertension. J Med Econ. 2012;15(3):500-508.
18. Rossano JW, Crystal MA, Morales DL, et al. Increasing prevalence and decreasing mortality in pulmonary hypertension related hospitalizations in the United States: an analysis of over 20,000 hospital admissions [abstract]. Circulation. 2011;124:A9251.
19. State & county quick facts: USA. US Census Bureau website. http://quickfacts.census.gov/qfd/states/00000.html. Accessed December 16, 2013.
20. Sieck S. The economics and reimbursement of congestive heart failure. In: Peacock WF, ed. Short Stay Management of Acute Heart Failure. New York, NY: Humana Press; 2012:9-32.
21. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.